<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36495262</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of medicine</Title><ISOAbbreviation>Ann Med</ISOAbbreviation></Journal><ArticleTitle>An <i>in situ</i> and <i>in&#xa0;vitro</i> investigation of cytoplasmic TDP-43 inclusions reveals the absence of a clear amyloid signature.</ArticleTitle><Pagination><StartPage>72</StartPage><EndPage>88</EndPage><MedlinePgn>72-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2022.2148734</ELocationID><Abstract><AbstractText><b>Introduction:</b> Several neurodegenerative conditions are associated with a common histopathology within neurons of the central nervous system, consisting of the deposition of cytoplasmic inclusions of TAR DNA-binding protein 43 (TDP-43). Such inclusions have variably been described as morphologically and molecularly ordered aggregates having amyloid properties, as filaments without the cross-&#x3b2;-structure and dye binding specific for amyloid, or as amorphous aggregates with no defined structure and fibrillar morphology.<b>Aims and Methods:</b> Here we have expressed human full-length TDP-43 in neuroblastoma x spinal cord 34 (NSC-34) cells to investigate the morphological, structural, and tinctorial properties of TDP-43 inclusions <i>in situ</i>. We have used last-generation amyloid diagnostic probes able to cross the cell membrane and detect amyloid in the cytoplasm and have adopted Raman and Fourier transform infrared microspectroscopies to study <i>in situ</i> the secondary structure of the TDP-43 protein in the inclusions. We have then used transmission electron microscopy to study the morphology of the TDP-43 inclusions.<b>Results:</b> The results show the absence of amyloid dye binding, the lack of an enrichment of cross-&#x3b2; structure in the inclusions, and of a fibrillar texture in the round inclusions. The aggregates formed <i>in&#xa0;vitro</i> from the purified protein under conditions in which it is initially native also lack all these characteristics, ruling out a clear amyloid-like signature.<b>Conclusions:</b> These findings indicate a low propensity of TDP-43 to form amyloid fibrils and even non-amyloid filaments, under conditions in which the protein is initially native and undergoes its typical nucleus-to-cell mislocalization. It cannot be excluded that filaments emerge on the long time scale from such inclusions, but the high propensity of the protein to form initially other types of inclusions appear to be an essential characteristic of TDP-43 proteinopathies.KEY MESSAGESCytoplasmic inclusions of TDP-43 formed in NSC-34 cells do not stain with amyloid-diagnostic dyes, are not enriched with cross-&#x3b2; structure, and do not show a fibrillar morphology.TDP-43 assemblies formed <i>in&#xa0;vitro</i> from pure TDP-43 do not have any hallmarks of amyloid.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cascella</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9856-6843</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banchelli</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5348-0552</Identifier><AffiliationInfo><Affiliation>Institute of Applied Physics "Nello Carrara", National Research Council, Sesto Fiorentino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abolghasem Ghadami</LastName><ForeName>Seyyed</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4093-4433</Identifier><AffiliationInfo><Affiliation>Department of Biotechnology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ami</LastName><ForeName>Diletta</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4549-8300</Identifier><AffiliationInfo><Affiliation>Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Milan Center of Neuroscience (NeuroMI), Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagliani</LastName><ForeName>Maria Cristina</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-2902-2719</Identifier><AffiliationInfo><Affiliation>Cellular Electron Microscopy Laboratory, Department of Experimental Medicine, University of Genova, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigi</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1067-6288</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staderini</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6993-4408</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tampellini</LastName><ForeName>Davide</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3188-0293</Identifier><AffiliationInfo><Affiliation>U 1195 INSERM-Universit&#xe9; Paris-Saclay, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Professeur Baulieu, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortese</LastName><ForeName>Katia</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9218-8933</Identifier><AffiliationInfo><Affiliation>Cellular Electron Microscopy Laboratory, Department of Experimental Medicine, University of Genova, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cecchi</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8387-7737</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natalello</LastName><ForeName>Antonino</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1489-272X</Identifier><AffiliationInfo><Affiliation>Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Milan Center of Neuroscience (NeuroMI), Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adibi</LastName><ForeName>Hadi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2064-7875</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matteini</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8488-5867</Identifier><AffiliationInfo><Affiliation>Institute of Applied Physics "Nello Carrara", National Research Council, Sesto Fiorentino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiti</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1330-1289</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med</MedlineTA><NlmUniqueID>8906388</NlmUniqueID><ISSNLinking>0785-3890</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">Lou Gehrig&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">MND</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">TDP-43 filaments</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>10</Day><Hour>8</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36495262</ArticleId><ArticleId IdType="pmc">PMC9746631</ArticleId><ArticleId IdType="doi">10.1080/07853890.2022.2148734</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arai T, Hasegawa M, Akiyama H, et al. . TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. . Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, et al. . Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61(5):427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CF, Eguchi H, Tagawa A, et al. . TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol. 2007;113(5):535&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">17333220</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, et al. . Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Leigh PN.. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic RM, Grinberg LT, Zidar J, et al. . ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol. 2008;15(8):772&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801606</ArticleId><ArticleId IdType="pubmed">18684309</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Iseki E, Yamamoto R, et al. . Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with lewy bodies. Brain Res. 2007;1184:284&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, et al. . TDP-43 immunoreactivity in hippocampal sclerosis and alzheimer&#x2019;s disease. Ann Neurol. 2007;61(5):435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H, Uryu K, Robinson J, et al. . Co-morbidity of TDP-43 proteinopathy in lewy body related diseases. Acta Neuropathol. 2007;114(3):221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C, Arai T, Hasegawa M, et al. . Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of huntington disease. J Neuropathol Exp Neurol. 2008;67(12):1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">19018245</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloh RH. TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. FEBS J. 2011;278(19):3539&#x2013;3549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177991</ArticleId><ArticleId IdType="pubmed">21777387</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, et al. . Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64(1):60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Xu Y, et al. . Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol. 2008;173(1):182&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438296</ArticleId><ArticleId IdType="pubmed">18535185</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday G, Bigio EH, Cairns NJ, et al. . Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathol. 2012;124(3):373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3445027</ArticleId><ArticleId IdType="pubmed">22878865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ.. Gains or losses: molecular mechanisms of TDP-43-mediated neurodegeneration. Nat Rev Neurosci. 2011;13(1):38&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R, Capitini C, Fani G, et al. . Quantification of the relative contributions of loss-of-function and gain-of-function mechanisms in TAR DNA-binding protein 43 (TDP-43) proteinopathies. J Biol Chem. 2016;291(37):19437&#x2013;19448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016682</ArticleId><ArticleId IdType="pubmed">27445339</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC.. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020;15(1):45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivoli Vega M, Nigro A, Luti S, et al. . Isolation and characterization of soluble human full-length TDP-43 associated with neurodegeneration. FASEB J. 2019;33(10):10780&#x2013;10793.</Citation><ArticleIdList><ArticleId IdType="pubmed">31287959</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM.. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem. 2017;86:27&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">28498720</ArticleId></ArticleIdList></Reference><Reference><Citation>Dapson RW. Amyloid from a histochemical perspective. A review of the structure, properties and types of amyloid, and a proposed staining mechanism for Congo red staining. Biotech Histochem. 2018;93(8):543&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">30403893</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson MD, Buxbaum JN, Eisenberg DS, et al. . Amyloid nomenclature 2020: update and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">33100054</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordana MT, Piccinini M, Grifoni S, et al. . TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol. 2010;20(2):351&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094784</ArticleId><ArticleId IdType="pubmed">19338576</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Ludolph A, Thal DR, et al. . Amyotrophic lateral sclerosis: dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord. Acta Neuropathol. 2010;120(1):67&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">20379728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Dickson DW.. Ultrastructural localization of TDP-43in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol. 2008;116(2):205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706695</ArticleId><ArticleId IdType="pubmed">18607609</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorpe JR, Tang H, Atherton J, et al. . Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy. J Neural Transm. 2008;115(12):1661&#x2013;1671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789307</ArticleId><ArticleId IdType="pubmed">18974920</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Geser F, Stieber A, et al. . TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol. 2013;125(1):121&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536927</ArticleId><ArticleId IdType="pubmed">23124365</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Masuda-Suzukake M, Arai T, et al. . Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4(1):124&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Arseni D, Hasegawa M, Murzin AG, et al. . Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022;601(7891):139&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612255</ArticleId><ArticleId IdType="pubmed">34880495</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Medina Cruz A, Hadley KC, et al. . Physiologically important electrolytes as regulators of TDP-43 aggregation and droplet-phase behavior. Biochemistry. 2019;58(6):590&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">30489059</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerman A, Liu HN, Croul S, et al. . Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol. 2010;119(3):335&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20111867</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Neumann M, Bigio EH, et al. . TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007;171(1):227&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941578</ArticleId><ArticleId IdType="pubmed">17591968</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitini C, Conti S, Perni M, et al. . TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amyloid and inherently toxic to neuroblastoma cells. PLOS One. 2014;9(1):e86720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3907574</ArticleId><ArticleId IdType="pubmed">24497973</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferri&#xe8;re F, Maniecka Z, P&#xe9;rez-Berlanga M, et al. . TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci. 2019;22(1):65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH, Wu JY, Deng HX, et al. . Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol. 2013;125(3):463&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593646</ArticleId><ArticleId IdType="pubmed">23378033</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A, Xiang X, Wang J, et al. . Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell. 2022;185(8):1346&#x2013;1355.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9018563</ArticleId><ArticleId IdType="pubmed">35247328</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang YX, Cao Q, Sawaya MR, et al. . Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43. Nature. 2022;605(7909):304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">35344984</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M, Arseni D, Bacioglu M, et al. . Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature. 2022;605(7909):310&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9095482</ArticleId><ArticleId IdType="pubmed">35344985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman NR, Durham HD, Blusztajn JK, et al. . Neuroblastoma&#x2009;&#xd7;&#x2009;spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn. 1992;194(3):209&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">1467557</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R, Fani G, Capitini C, et al. . Quantitative assessment of the degradation of aggregated TDP-43 mediated by the ubiquitin proteasome system and macroautophagy. Faseb J. 2017;31(12):5609&#x2013;5624.</Citation><ArticleIdList><ArticleId IdType="pubmed">28842427</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, et al. . Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Magrane J, Takahashi RH, et al. . Internalized antibodies to the abeta domain of APP reduce neuronal abeta and protect against synaptic alterations. J Biol Chem. 2007;282(26):18895&#x2013;18906.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468102</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigi A, Loffredo G, Cascella R, et al. . Targeting pathological amyloid aggregates with conformation-sensitive antibodies. Curr Alzheimer Res. 2020;17(8):722&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">33167834</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlgren KN, Manelli AM, Stine WB Jr., et al. . Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002;277(35):32046&#x2013;32053.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058030</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Page MJ, Hendricks L, et al. . Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment with novel Amytracker&#x2122; stains. J R Soc Interface. 2018;15(139):20170941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5832738</ArticleId><ArticleId IdType="pubmed">29445039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadami SA, Hossein-Pour Z, Khodarahmi R, et al. . Synthesis and in&#xa0;vitro characterization of some benzothiazole-and benzofuranone-derivatives for quantification of fibrillar aggregates and inhibition of amyloid-mediated peroxidase activity. Med Chem Res. 2013;22(1):115&#x2013;126.</Citation></Reference><Reference><Citation>Ghadami SA, Shevidi S, Hosseinzadeh L, et al. . Synthesis and in&#xa0;vitro quantification of amyloid fibrils by barbituric and thiobarbituric acid-based chromene derivatives. Biophys Chem. 2021;269:106522.</Citation><ArticleIdList><ArticleId IdType="pubmed">33352334</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J, Letellier G, Marin A, et al. . Protein secondary structure assignment revisited: a detailed analysis of different assignment methods. BMC Struct Biol. 2005;5:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1249586</ArticleId><ArticleId IdType="pubmed">16164759</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez MAS, Bassani-Sternberg M, Coukos G, et al. . Analysis of secondary structure biases in naturally presented HLA-I ligands. Front Immunol. 2019;10:2731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6883762</ArticleId><ArticleId IdType="pubmed">31824508</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Taddei N, Stefani M, et al. . Reduction of the amyloidogenicity of a protein by specific binding of ligands to the native conformation. Protein Sci. 2001;10(4):879&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2373972</ArticleId><ArticleId IdType="pubmed">11274479</ArticleId></ArticleIdList></Reference><Reference><Citation>Rygula A, Majzner K, Marzec KM, et al. . Raman spectroscopy of proteins: a review. J Raman Spectrosc. 2013;44(8):1061&#x2013;1076.</Citation></Reference><Reference><Citation>Atlante A, Calissano P, Bobba A, et al. . Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death. J Biol Chem. 2000;275(47):37159&#x2013;37166.</Citation><ArticleIdList><ArticleId IdType="pubmed">10980192</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Liu J, Tian L, et al. . Raman micro-spectroscopy monitoring of cytochrome c redox state in Candida utilis during cell death under low-temperature plasma-induced oxidative stress. Analyst. 2020;145(11):3922&#x2013;3930.</Citation><ArticleIdList><ArticleId IdType="pubmed">32307505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ami D, Lavatelli F, Rognoni P, et al. . In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. Sci Rep. 2016;6:29096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931462</ArticleId><ArticleId IdType="pubmed">27373200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ami D, Mereghetti P, Leri M, et al. . A FTIR microspectroscopy study of the structural and biochemical perturbations induced by natively folded and aggregated transthyretin in HL-1 cardiomyocytes. Sci Rep. 2018;8(1):12508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6104026</ArticleId><ArticleId IdType="pubmed">30131519</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H. III. Thioflavine T interaction with synthetic alzheimer&#x2019;s disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2(3):404&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142377</ArticleId><ArticleId IdType="pubmed">8453378</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue C, Yuwen Lin T, Chang D, et al. . Thioflavin T as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation. R Soc Open Sci. 2017;4(1):160696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5319338</ArticleId><ArticleId IdType="pubmed">28280572</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Bucciantini M, Capanni C, et al. . Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N-terminal domain. Protein Sci. 2001;10(12):2541&#x2013;2547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2374049</ArticleId><ArticleId IdType="pubmed">11714922</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldi G, Bemporad F, Torrassa S, et al. . Amyloid formation of a protein in the absence of initial unfolding and destabilization of the native state. Biophys J. 2005;89(6):4234&#x2013;4244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1366988</ArticleId><ArticleId IdType="pubmed">16169977</ArticleId></ArticleIdList></Reference><Reference><Citation>Picotti P, De Franceschi G, Frare E, et al. . Amyloid fibril formation and disaggregation of fragment 1-29 of apomyoglobin: insights into the effect of pH on protein fibrillogenesis. J Mol Biol. 2007;367(5):1237&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pubmed">17320902</ArticleId></ArticleIdList></Reference><Reference><Citation>Motamedi-Shad N, Monsellier E, Torrassa S, et al. . Kinetic analysis of amyloid formation in the presence of heparan sulfate: faster unfolding and change of pathway. J Biol Chem. 2009;284(43):29921&#x2013;29934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785621</ArticleId><ArticleId IdType="pubmed">19700762</ArticleId></ArticleIdList></Reference><Reference><Citation>Sicorello A, Torrassa S, Soldi G, et al. . Agitation and high ionic strength induce amyloidogenesis of a folded PDZ domain in native conditions. Biophys J. 2009;96(6):2289&#x2013;2298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717264</ArticleId><ArticleId IdType="pubmed">19289055</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokri MM, Ahmadian S, Bemporad F, et al. . Amyloid fibril formation by a normally folded protein in the absence of denaturants and agitation. Amyloid. 2013;20(4):226&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">24053331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramshini H, Tayebee R, Bigi A, et al. . Identification of novel 1,3,5-triphenylbenzene derivative compounds as inhibitors of hen lysozyme amyloid fibril formation. Int J Mol Sci. 2019;20(22):5558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6888386</ArticleId><ArticleId IdType="pubmed">31703381</ArticleId></ArticleIdList></Reference><Reference><Citation>Medinas DB, Rozas P, Mart&#xed;nez Traub F, et al. . Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2018;115(32):8209&#x2013;8214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6094144</ArticleId><ArticleId IdType="pubmed">30038021</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitini C, Fani G, Vivoli Vega M, et al. . Full-length TDP-43 and its C-terminal domain form filaments in&#xa0;vitro having non-amyloid properties. Amyloid. 2021;28(1):56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613275</ArticleId><ArticleId IdType="pubmed">33026249</ArticleId></ArticleIdList></Reference><Reference><Citation>Hintermayer MA, Volkening K, Moszczynski AJ, et al. . Tau protein phosphorylation at thr 175 initiates fibril formation via accessibility of the N-terminal phosphatase-activating domain. J Neurochem. 2020;155(3):313&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">31853971</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberti MJ, Bertoncini CW, Klement R, et al. . Fluorescence imaging of amyloid formation in living cells by a functional, tetracysteine-tagged alpha-synuclein. Nat Methods. 2007;4(4):345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko L-W, Ko H-HC, Lin W-L, et al. . Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. J Neuropathol Exp Neurol. 2008;67(11):1084&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768257</ArticleId><ArticleId IdType="pubmed">18957893</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedini A, Raleigh DP.. A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides. Protein Eng Des Sel. 2009;22(8):453&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719502</ArticleId><ArticleId IdType="pubmed">19596696</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, et al. . TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosislinked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284(30):20329&#x2013;20339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Kaneko K, Watanabe S, et al. . A seeding reaction recapitulates intracellular formation of sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem. 2011;286(21):18664&#x2013;18672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3099683</ArticleId><ArticleId IdType="pubmed">21454603</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlomagno Y, Zhang Y, Davis M, et al. . Casein kinase II induced polymerization of soluble TDP-43 into filaments is inhibited by heat shock proteins. PLOS One. 2014;9(3):e90452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942448</ArticleId><ArticleId IdType="pubmed">24595055</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang YS, Tsai KJ, Chang YJ, et al. . Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat Commun. 2014;5:4824.</Citation><ArticleIdList><ArticleId IdType="pubmed">25215604</ArticleId></ArticleIdList></Reference><Reference><Citation>Staderini T, Bigi A, Mongiello D, Cecchi C, Chiti F. Biophysical Characterization of Full Length TAR DNA Binding Protein (TDP-43) Phase Separation. Protein Sci. 2022; e4509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9703588</ArticleId><ArticleId IdType="pubmed">36371546</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposto JC, Martic S.. Phosphorylated TAR DNA-binding protein-43: aggregation and antibody-based inhibition. Biochim Biophys Acta Mol Basis Dis. 2021;1867(12):166234.</Citation><ArticleIdList><ArticleId IdType="pubmed">34339840</ArticleId></ArticleIdList></Reference><Reference><Citation>Doke AA, Jha SK.. Effect of in&#xa0;vitro solvation conditions on inter- and intramolecular assembly of Full-Length TDP-43. J Phys Chem B. 2022;126(26):4799&#x2013;4813.</Citation><ArticleIdList><ArticleId IdType="pubmed">35758053</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L, Wei Y, Lu Y, et al. . ALS-causing mutations significantly perturb the self-assembly and interaction with nucleic acid of the intrinsically disordered Prion-like domain of TDP-43. PLOS Biol. 2016;14(1):e1002338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4703307</ArticleId><ArticleId IdType="pubmed">26735904</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang LL, Che MX, Zhao J, et al. . Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J Biol Chem. 2013;288(27):19614&#x2013;19624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707662</ArticleId><ArticleId IdType="pubmed">23689371</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Chen Y, Zhou X, et al. . An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat Struct Mol Biol. 2011;18(7):822&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357956</ArticleId><ArticleId IdType="pubmed">21666678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AK, Lin RY, Hsieh EZ, et al. . Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J Am Chem Soc. 2010;132(4):1186&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">20055380</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Boyer DR, Sawaya MR, et al. . Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nat Struct Mol Biol. 2019;26(7):619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047951</ArticleId><ArticleId IdType="pubmed">31235914</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther EL, Ge P, Trinh H, et al. . Atomic-level evidence for packing and positional amyloid polymorphism by segment from TDP-43 RRM2. Nat Struct Mol Biol. 2018;25(4):311&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6056015</ArticleId><ArticleId IdType="pubmed">29531287</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Babinchak WM, Surewicz WK.. Cryo-EM structure of amyloid fibrils formed by the entire low complexity domain of TDP-43. Nat Commun. 2021;12(1):1620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955110</ArticleId><ArticleId IdType="pubmed">33712624</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramshini H, Parrini C, Relini A, et al. . Large proteins have a great tendency to aggregate but a low propensity to form amyloid fibrils. PLOS One. 2011;6(1):e16075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020945</ArticleId><ArticleId IdType="pubmed">21249193</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R, Bigi A, Riffert DG, et al. . A quantitative biology approach correlates neuronal toxicity with the largest inclusions of TDP-43. Sci Adv. 2022;8(30):eabm6376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9328675</ArticleId><ArticleId IdType="pubmed">35895809</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>